SEARCH:   Advanced

Blood, 1 October 2006, Vol. 108, No. 7, pp. 2159-2164. Prepublished online as a Blood First Edition Paper on June 8, 2006; DOI 10.1182/blood-2006-03-013086. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-013086v1 108/7/2159    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Offidani, M. Articles by Leoni, P. Search for Related Content PubMed PubMed Citation Articles by Offidani, M. Articles by Leoni, P. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 28, 2006 Accepted May 17, 2006 Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for newly diagnosed multiple myeloma patients over 65 years Massimo Offidani*, Laura Corvatta, Maria-Novella Piersantelli, Giuseppe Visani, Francesco Alesiani, Marino Brunori, Piero Galieni, Massimo Catarini, Maurizio Burattini, Riccardo Centurioni, Mario Ferranti, Serena Rupoli, Anna Rita Scortechini, Luciano Giuliodori, Marco Candela, Debora Capelli, Mauro Montanari, Attilio Olivieri, Antonella Poloni, Claudia Polloni, Monica Marconi, and Pietro Leoni Clinica di Ematologia Divisione Medicina Fabriano Clinica di Ematologia Polo Ospedaliero Universitario Ospedali Riuniti Universita Ancona Divisione Ematologia Pesaro Unita di Oncoematologia S, Severino Marche Divisione Medicina Fano Divisione di Ematologia Ascoli Piceno Divisione Medicina Macerata Divisione Medicina Jesi Divisione Medicina Civitanova Marche Divisione Medicina Tolentino Servizio di Oncologia Fabriano * Corresponding author; email: m.offidani{at}ao-umbertoprimo.marche.it. We present the results of a phase II study using thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) in the treatment of 50 newly diagnosed multiple myeloma patients over 65 years. Thalidomide was administered orally 100 mg at bedtime continuously, dexamethasone orally 40 mg days 1-4 and 9-12 and pegylated liposomal doxorubicin intravenously 40 mg/m2 on day 1 over the 28-days cycle. Response was assessed according to the EBMT criteria. Seventeen (34%) patients achieved CR, 7 (14%) nCR, 5 (10%) VGPR, 15 (30%) PR and 5 (10%) MR resulting in an ORR of 98%. Only one patient (2%) presented progressive disease. Time to progression (TTP), event-free survival (EFS) and overall survival (OS) projected at 3 years were 60%, 57% and 74% respectively, and these parameters were significantly higher in those patients achieving a response VGPR versus those who did not. Grade 3-4 nonhematologic adverse events were constipation (10%), fatigue (6%), tremors (4%), mucositis (4%) and palmar-plantar erythro-dysesthesia (2%). Grade 3-4 neutropenia occurred in 12% of patients. Grade 3-4 infections and thrombo-embolic accidents were observed in 22% and 14% of patients, respectively. In the treatment of elderly patients with newly diagnosed multiple myeloma, ThaDD is a very effective regimen with manageable toxicity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Complete response in myeloma: a Trojan horse? Bart Barlogie and Guido Tricot Blood 2006 108: 2134. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020